[1] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol, 2018, 3:383-403.
[2] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67:370-398.
[3] Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology, 2015, 61:712-721.
[4] Wang L, Zou ZQ, Wang K. Clinical relevance of HLA gene variants in HBV infection. J Immunol Res, 2016:9069375.
[5] Wasityastuti W, Yano Y, Ratnasari N, et al. Protective effects of HLA-DPA1/DPB1 variants against Hepatitis B virus infection in an Indonesian population. Infect Genet Evol, 2016, 41:177-184.
[6] Trinks J, Nishida N, Hulaniuk M. L, et al. Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population. Liver Int, 2017, 37:1476-1487.
[7] Yu L, Cheng YJ, Cheng ML, et al. Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development. Sci Rep, 2015, 5:14933.
[8] Xu T, Sun M, Wang H. Relationship between HLA-DQ gene polymorphism and hepatitis B virus infection. Biomed Res Int, 2017:9679843.
[9] Xu T, Zhu A, Sun M, et al. Quantitative assessment of HLA-DQ gene polymorphisms with the development of hepatitis B virus infection, clearance, liver cirrhosis, and hepatocellular carcinoma. Oncotarget, 2017, 9:96-109.
[10] Huang JM, Xiong LS, Wang J, et al. Association between the HLA-DQB1 polymorphisms and the susceptibility of chronic hepatitis B: a comprehensive meta-analysis. Biomed Rep, 2016, 4:557-566.
[11] Seshasubramanian V, Soundararajan G, Ramasamy P. Human leukocyte antigen A, B and hepatitis B infection outcome: a meta-analysis. Infect Genet Evol, 2018, 66:392-398.
[12] Zidi I, Laaribi AB, Bortolotti D, et al. HLA-E polymorphism and soluble HLA-E plasma levels in chronic hepatitis B patients. HLA, 2016, 87:153-159.
[13] Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol, 2016, 16(8):509-523.
[14] Zhao J, Zhang X, Fang L, et al. Association between IL28B polymorphisms and outcomes of hepatitis B virus infection: a meta-analysis. BMC Med Genet, 2020, 21:88.
[15] Sun Y, Lu Y, Li T, et al. Interferon gamma +874T/A polymorphism increases the risk of hepatitis virus-related diseases: evidence from a meta-analysis. PLoS One, 2015, 10:e0121168.
[16] Ma Z, Liu J, Wu W, et al. The IL-1R/TLR signaling pathway is essential for efficient CD8+ T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. Cell Mol Immunol, 2017, 14:997-1008.
[17] Huang X, Li H, Wang J, et al. Genetic polymorphisms in Toll-like receptor 3 gene are associated with the risk of hepatitis B virus-related liver diseases in a Chinese population. Gene, 2015, 569:218-224.
[18] Geng PL, Song LX, An H, et al. Toll-like receptor 3 is associated with the risk of HCV infection and HBV-related diseases. Medicine (Baltimore), 2016, 95:e2302.
[19] Al-Qahtani A A, Al-Anazi M R, Nazir N, et al. Association of single nucleotide polymorphisms in microRNAs with susceptibility to hepatitis B virus infection and HBV-related liver complications: a study in a Saudi Arabian population. J Viral Hepat, 2017, 24:1132-1142.
[20] Zhou GQ, Meng H, Wang JR, et al. Functional polymorphisms in microRNA gene and hepatitis B risk among Asian population: a meta-analysis. Genet Mol Res, 2015, 14:4767-4777.
[21] Bandopadhyay M, Bharadwaj M. Exosomal miRNAs in hepatitis B virus related liver disease: a new hope for biomarker. Gut Pathog, 2020, 12:23.
[22] He Q, Huang Y, Zhang L, et al. Association between vitamin D receptor polymorphisms and hepatitis B virus infection susceptibility: a meta-analysis study. Gene, 2018, 645:105-112. |
